OBJECTIVE: Oxybutynin is the current gold standard drug for management of overactive bladder (OAB) in children, but can have significant side effects or be difficult to administer in multiple daily doses.
Herein, we report our experience with transdermal oxybutynin patch (TOP) as an alternative in a selected patient population without neuropathic compromise.
MATERIALS AND METHODS: Consecutive patients assessed in a pediatric urology clinic over a 1-year period, diagnosed with OAB with minimum follow-up of 3 months, were included. TOP starting dose was 3.9 mg/day based on product design (Oxytrol). Demographics and outcomes data were retrospectively collected. Symptomatic response was defined as improvement or resolution of lower urinary tract symptoms.
RESULTS: 35 children met inclusion criteria (mean age 8 years, range 4-16). Overall, 97% reported good symptom response. The main side effect was skin irritation at TOP site (35%), leading to discontinuation in 20%. There were no reports of other significant side effects. Mean bladder capacity increased from 104 ml to 148 ml at follow-up.
CONCLUSIONS: Our data suggest that TOP is a viable alternative for children with non-neuropathic OAB who do not tolerate other formulations of oxybutynin. These findings highlight the potential benefit of transdermal drug delivery in the pediatric setting.
Written by:
Gleason JM, Daniels C, Williams K, Varghese A, Koyle MA, Bägli DJ, Pippi Salle JL, Lorenzo AJ. Are you the author?
Division of Urology, The Hospital for Sick Children, Department of Surgery, The University of Toronto, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada. ;
Reference: J Pediatr Urol. 2014 Jan 17. pii: S1477-5131(14)00020-5.
doi: 10.1016/j.jpurol.2013.12.017
PubMed Abstract
PMID: 24477421
UroToday.com Overactive Bladder (OAB) Section
